Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01382095 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01382095 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 40 participants.
The verdict
NCT01382095, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if immunization with a recombinant E. coli protein, dscCfaE, is safe and immunogenic when administered through the skin using a patch.
Interventions
- BIOLOGICAL Recombinant fimbrial adhesin dscCfaE
- BIOLOGICAL Modified E. coli heat labile enterotoxin LTR192G
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01382095
The ClinicalTrials.gov registry entry for NCT01382095 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Recombinant fimbrial adhesin dscCfaE is the first listed.
NCT01382095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01382095 about?
NCT01382095 is a clinical study titled "Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea". The purpose of the study is to determine if immunization with a recombinant E. coli protein, dscCfaE, is safe and immunogenic when administered through the skin using a patch.
What is the current status of trial NCT01382095?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2011-07. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01382095?
The interventions under investigation include: Recombinant fimbrial adhesin dscCfaE (BIOLOGICAL), Modified E. coli heat labile enterotoxin LTR192G (BIOLOGICAL).
Who is sponsoring clinical trial NCT01382095?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.